Dysbiosis of salivary microbiota in inflammatory bowel disease and its association with oral immunological biomarkers

DNA Research

Volumn 21, Issue 1, 2014, Pages 15-25

  Said, Heba S ^a   Suda, Wataru ^a   Nakagome, Shigeki ^b   Chinen, Hiroshi ^c   Oshima, Kenshiro ^a   Kim, Sangwan ^a   Kimura, Ryosuke ^c   Iraha, Atsushi ^c   Ishida, Hajime ^c   Fujita, Jiro ^c   Mano, Shuhei ^b   Morita, Hidetoshi ^d   Dohi, Taeko ^e   Oota, Hiroki ^f   Hattori, Masahira ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^c UNIVERSITY OF THE RYUKYUS   (Japan)

^d AZABU UNIVERSITY   (Japan)

^e NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^f KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

16S rRNA; Crohn's disease; pyrosequencing; salivary microbiota; ulcerative colitis

Indexed keywords

16S RRNA; CROHN'S DISEASE; PYROSEQUENCING; SALIVARY MICROBIOTA; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; DYSBIOSIS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; METAGENOME; MICROBIOTA; MIDDLE AGED; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; SALIVA;

EID: 84894541081     PISSN: 13402838     EISSN: 17561663     Source Type: Journal    
DOI: 10.1093/dnares/dst037     Document Type: Article

References (66)

1. Metzker, M.L. 2010, Sequencing technologies-the next generation, Nat. Rev. Genet., 11, 31-46.
2. Kunin, V., Copeland, A., Lapidus, A., Mavromatis, K. and Hugenholtz, P. 2008, A bioinformatician's guide to metagenomics, Microbiol. Mol. Biol. Rev., 72, 557-78.
3. Hamady, M. and Knight, R. 2009, Microbial community profiling for human microbiome projects: tools, techniques, and challenges, Genome Res., 19, 1141-52.
4. Kuczynski, J., et al. 2012, Experimental and analytical tools for studying the human microbiome, Nat. Rev. Genet., 13, 47-58.
5. Song, S., Jarvie, T. and Hattori, M. 2013, Our second genome-human metagenome-how next generation sequencer changes our life through microbiology, Adv. Microb. Physiol., 62, 119-44.
6. Jumpstart Consortium Human Microbiome Project Data Generation Working Group. 2012, Evaluation of 16S rDNA-based community profiling for human microbiome research, PLoS ONE, 6, e39315.
7. Andersson, A.F., Lindberg, M., Jakobsson, H., Bäckhed, F., Nyrén, P. and Engstrand, L. 2008, Comparative analysis of human gut microbiota by barcoded pyrosequencing, PLoS ONE, 3, e2836.
8. Wang, Y. and Qian, P.Y. 2009, Conservative fragments in bacterial 16S rRNA genes and primer design for 16S ribosomalDNA amplicons in metagenomic studies, PLoSONE, 4, e7401.
9. Hamady, M.,Walker, J.J., Harris, J.K.,Gold, N.J.andKnight, R. 2008, Error-correcting barcoded primers for pyrosequencing hundreds of samples in multiplex, Nat. Methods, 5, 235-7.
10. Kim, S.W., Suda,W., Kim, S., et al. 2013, Robustness of gut microbiota of healthy adults in response to probiotic intervention revealed by high-throughput pyrosequencing, DNA Res., 20, 241-53.
11. Starke, E.M., et al. 2006, Technology development to explore the relationship between oral health and the oral microbial community, BMC Oral Health, 6(Suppl. 1), S10.
12. Avila, M., Ojcius, D.M. and Yilmaz, O. 2009, The oral microbiota: living with a permanent guest, DNA Cell Biol., 28, 405-11.
13. Dewhirst, F.E., Chen, T., Izard, J., et al. 2010, The human oral microbiome, J. Bacteriol., 192, 5002-17.
14. Curtis, M.A., Zenobia, C. andDarveau, R.P. 2011, The relationship of the oral microbiotia to periodontal health and disease, Cell Host Microbe., 10, 302-6.
15. Jose, F.A. and Heyman, M.B. 2008, Extraintestinal manifestations of inflammatory bowel disease, J. Pediatr. Gastroenterol. Nutr., 46, 124-33.
16. Femiano, F., Lanza, A., Buonaiuto, C., Perillo, L., Dell'Ermo,A. andCirillo, N.2009,Pyostomatitis vegetans: a review of the literature, Med. Oral Patol. Oral Cir. Bucal., 14, E114-117.
17. Rowland, M., Fleming, P. and Bourke, B. 2010, Looking in the mouth for Crohn's disease, Inflamm. Bowel Dis., 16, 332-7.
18. Veloso, F.T. 2011, Extraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome? World J. Gastroenterol., 17, 2702-7.
19. Vavricka, S.R., Brun, L., Ballabeni, P., et al. 2011, Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort, Am. J. Gastroenterol., 106, 110-9.
20. Singhal, S., Dian, D., Keshavarzian, A., Fogg, L., Fields, J.Z. and Farhadi, A. 2011, The role of oral hygiene in inflammatory bowel disease, Dig. Dis. Sci., 56, 170-5.
21. Xavier, R.J. and Podolsky, D.K. 2007, Unravelling the pathogenesis of inflammatory bowel disease, Nature, 448, 427-34.
22. Cho, J.H. 2008, The genetics and immunopathogenesis of inflammatory bowel disease, Nat. Rev. Immunol., 8, 458-66.
23. Peterson, D.A., Frank, D.N., Pace, N.R. and Gordon, J.I. 2008, Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases, Cell Host Microbe, 3, 417-27.
24. Maloy, K.J. and Powrie, F. 2011, Intestinal homeostasis and its breakdown in inflammatory bowel disease, Nature, 474, 298-306.
25. Khor, B., Gardet, A. and Xavier, R.J. 2011, Genetics and pathogenesis of inflammatory bowel disease, Nature, 474, 307-17.
26. Maynard, C.L., Elson, C.O., Hatton, R.D. and Weaver, C.T. 2012, Reciprocal interactions of the intestinal microbiota and immune system, Nature, 489, 231-41.
27. Greenberg, G.R. 2004, Antibiotics should be used as firstline therapy for Crohn's disease, Inflamm. Bowel. Dis., 10, 318-20.
28. Sellon, R.K., Tonkonogy, S., Schultz, M., et al. 1998, Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice, Infect. Immun., 66, 5224-31.
29. Manichanh, C., Rigottier-Gois, L., Bonnaud, E., et al. 2006, Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach, Gut, 55, 205-11.
30. Baumgart, M., Dogan, B., Rishniw, M., et al. 2007, Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum, ISME J., 1, 403-18.
31. Frank, D.N., St Amand, A.L., Feldman, R.A., Boedeker, E.C., Harpaz, N. and Pace, N.R. 2007, Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases, Proc. Natl Acad. Sci. USA, 104, 13780-5.
32. Dicksved, J., Halfvarson, J., Rosenquist, M., et al. 2008, Molecular analysis of the gut microbiota of identical twins with Crohn's disease, ISME J., 2, 716-27.
33. Sokol, H., Pigneur, B., Watterlot, L., et al. 2008, Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients, Proc. Natl Acad. Sci. USA, 105, 16731-6.
34. Qin, J., Li, R., Raes, J., et al. 2010, A human gut microbial gene catalogue established by metagenomic sequencing, Nature, 464, 59-65.
35. Morita, H., Kuwahara, T., Ohshima, K., et al. 2007, An improved DNA isolation method for metagenomic analysis of the microbial flora of the human intestine, Microbes Environ., 22, 214-22.
36. Lozupone, C., Hamady,M. and Knight, R. 2006, UniFrac-anonline tool forcomparing microbialcommunitydiversity in a phylogenetic context, BMCBioinformatics,7, 371.
37. Gotelli, N.J. and Colwell, R.K. 2011, Estimating species richness, In: Magurran, A.E. and McGill, B.J. (eds.), Frontiers in measuring biodiversity. Oxford University Press: Oxford, UK, pp. 39-54.
38. Colwell, R.K. 2009, Biodiversity: concepts, patterns, and measurement, In: Levin, S.A., et al. (eds.), The Princeton guide to ecology. Princeton University Press: New Jersey, USA, pp. 257-63.
39. Hattori, M. and Taylor, T.D. 2009, The human intestinal microbiome: a new frontier of human biology, DNA Res., 16, 1-12.
40. Kunin, V., Engelbrektson, A., Ochman, H. and Hugenholtz, P. 2010,Wrinkles in the rare biosphere: pyrosequencing errors can lead to artificial inflation of diversity estimates, Environ. Microbiol., 12, 118-23.
41. Keijser, B.J., Zaura, E., Huse, S.M., et al. 2008, Pyrosequencing analysis of the oral microflora of healthy adults, J. Dent. Res., 87, 1016-20.
42. Nasidze, I., Li, J., Quinque, D., Tang, K. and Stoneking, M. 2009, Global diversity in the human salivary microbiome, Genome Res., 19, 636-43.
43. Diaz, P.I.,Dupuy, A.K., Abusleme, L., et al. 2012, Using high throughput sequencing to explore the biodiversity in oral bacterial communities, Mol. Oral Microbiol., 27, 182-201.
44. Yamanaka, W., Takeshita, T., Shibata, Y., et al. 2012, Compositional stability of a salivary bacterial population against supragingival microbiota shift following periodontal therapy, PLoS ONE, 7, e42806.
45. Yang, F., Zeng, X., Ning, K., et al. 2012, Saliva microbiomes distinguish caries-active from healthy human populations, ISME J., 6, 1-10.
46. Paju, S., Pussinen, P.J., Suominen-Taipale, L., Hyvönen, M., Knuuttila, M. and Könönen, E. 2009, Detection of multiple pathogenic species in saliva is associated with periodontal infection in adults, J. Clin. Microbiol., 47, 235-8.
47. Mager, D.L., Haffajee, A.D., Devlin, P.M., Norris, C.M., Posner, M.R. and Goodson, J.M. 2005, The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects, J. Transl. Med., 3, 27.
48. Farrell, J.J., Zhang, L., Zhou, H., et al. 2012, Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer, Gut, 61, 582-8.
49. Koren, O., Spor, A., Felin, J., et al. 2011, Human oral, gut, and plaque microbiota in patients with atherosclerosis, Proc. Natl Acad. Sci. USA, 108(Suppl. 1), 4592-8.
50. Poveda-Roda, R., Jiménez, Y., Carbonell, E., Gavaldá, C., Margaix-Muñoz, M.M. and Sarrión-Pérez, G. 2008, Bacteremia originating in the oral cavity. A review, Med. Oral. Patol. Oral Cir. Bucal., 13, E355-362.
51. Parahitiyawa, N.B., Jin, L.J., Leung, W.K., Yam, W.C. and Samaranayake, L.P. 2009, Microbiology of odontogenic bacteremia: beyond endocarditis, Clin. Microbiol. Rev., 22, 46-64, Table of Contents.
52. Alauze, C.,Marchandin, H. and Lozniewski, A. 2010, New insights into Prevotella diversity and medical microbiology, Future Microbiol., 5, 1695-718.
53. Oakley, B.B., Fiedler, T.L.,Marrazzo, J.M. and Fredricks, D.N. 2008, Diversity of human vaginal bacterial communities and associations with clinically defined bacterial vaginosis, Appl. Environ. Microbiol., 74, 4898-909.
54. Yang, L., Lu, X., Nossa,C.W., Francois, F., Peek, R.M.andPei, Z. 2009, Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome, Gastroenterology, 137, 588-97.
55. Li, X.X., Wong, G.L., To, K.F., et al. 2009, Bacterial microbiota profiling in gastritis without Helicobacter pylori infection or non-steroidal anti-inflammatory drug use, PLoS ONE, 4, e7985.
56. Darveau, R.P. 2010, Periodontitis: a polymicrobial disruption of host homeostasis, Nat. Rev. Microbiol., 8, 481-90.
57. Farnaud, S.J., Kosti, O., Getting, S.J. and Renshaw, D. 2010, Saliva: physiology and diagnostic potential in health and disease, ScientificWorldJournal, 10, 434-56.
58. Szczeklik, K., Owczarek, D., Pytko-Polonczyk, J., Kesek, B. and Mach, T.H. 2012, Proinflammatory cytokines in the saliva of patients with active and non-active Crohn's disease, Pol. Arch. Med.Wewn., 122, 200-8.
59. Rathnayake, N., Akerman, S., Klinge, B., et al. 2013, Salivary biomarkers for detection of systemic diseases, PLoS ONE, 8, e61356.
60. Savage, N.W., Barnard, K., Shirlaw, P.J., et al. 2004, Serum and salivary IgA antibody responses to Saccharomyces cerevisiae, Candida albicans and Streptococcus mutans in orofacial granulomatosis and Crohn's disease, Clin. Exp. Immunol., 135, 483-9.
61. Wiesner, J. and Vilcinskas, A. 2010, Antimicrobial peptides: the ancient arm of the human immune system, Virulence, 1, 440-64.
62. Surna, A., Kubilius, R., Sakalauskiene, J., et al. 2009, Lysozyme and microbiota in relation to gingivitis and periodontitis, Med. Sci. Monit., 15, CR66-73.
63. Abraham, B.P. and Thirumurthi, S. 2009, Clinical significance of inflammatory markers, Curr. Gastroenterol. Rep., 11, 360-7.
64. Ellison, R.T. 3rd and Giehl, T.J. 1991, Killing of gram-negative bacteria by lactoferrin and lysozyme, J. Clin. Invest., 88, 1080-91.
65. Melmed, G.Y. and Targan, S.R. 2010, Future biologic targets for IBD: potentials and pitfalls, Nat. Rev. Gastroenterol. Hepatol., 7, 110-7.
66. Koenig, J.E., Spor, A., Scalfone, N., et al. 2011, Succession of microbial consortia in the developing infant gut microbiome, Proc. Natl Acad. Sci. USA, 108(Suppl. 1), 4578-85.